Don’t expect price-gouging for COVID-19 vaccine, says expert
Given the scale of economic devastation that’s occurred around the world thanks to COVID-19, the hundreds of pharmaceutical companies searching for a vaccine might be forgiven for thinking that whoever finds it first should be able to name their price. But according to one health economist, there are far more important factors to consider than normal supply and demand. “When you have an infection that is endemic in the population, what you need is for the vaccine to achieve herd immunity, and that means you need to get between 60 and 80 per cent of the current population vaccinated,” said Christopher McCabe of the University of Alberta in an interview with Folio. As explained by McCabe, who’s also the head of Alberta’s Institute of Health Economics, setting the price too high risks the possibility that not enough people in the population get vaccinated, which defeats the purpose of aiming for herd immunity. Citing work by Tufts University, McCabe said the standard estimated cost of research and development for a new drug is US$1.3 billion, which takes into account sunk costs incurred from the vast majority of prospects that don’t make it past the hurdles of clinical trials and regulatory approval....